U.S. probe into German drug pricing may spark tariffs on pharmaceutical importsExecutive summary: U.S. trade officials have launched an investigation into German pharmaceutical pricing, alleging that Germany does not cover its share of research and development costs. If tariffs are imposed, they could raise drug prices in the United States and strain transatlantic trade relations. U.S. Trade Representative Katherine Tai, German pharmaceutical companies, the German government. The investigation is expected to move toward potential tariff measures, which may be contested in courts and could affect future U.S.-German trade negotiations.U.S. trade officials have launched an investigation into German pharmaceutical pricing, alleging that Germany does not cover its share of research and development costs. If tariffs are imposed, they could raise drug prices in the United States and strain transatlantic trade relations. The probe focuses on the pricing gap rather than production costs and could affect U.S.-German trade relations.Connected developmentsAn allegedly unfair pricing probe could bring US tariffsEU prepares tariffs on Chinese plug‑in hybridsAngeblich unfaire Preise: US-Untersuchung wegen deutscher Arzneipreise - Zölle drohenOpen the full case file on Beyond →
Social Pulse
AI estimate · not scraped